131 related articles for article (PubMed ID: 37545223)
21. A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: multi-cancer analyses of associated survival rates.
Chobrutskiy BI; Yeagley M; Diviney A; Zaman S; Gozlan EC; Tipping P; Koohestani DM; Roca AM; Blanck G
Immunology; 2020 Apr; 159(4):373-383. PubMed ID: 31821535
[TBL] [Abstract][Full Text] [Related]
22. Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma.
Chobrutskiy BI; Yeagley M; Tipping P; Zaman S; Diviney A; Patel DN; Falasiri S; Uversky VN; Blanck G
Oncogene; 2020 Feb; 39(8):1773-1783. PubMed ID: 31740784
[TBL] [Abstract][Full Text] [Related]
23. Exploiting big data survival information to unify risk-stratification related, adaptive immune receptor parameters for multiple myeloma.
Wolmarans HJ; Barker VR; Chobrutskiy A; Chobrutskiy BI; Huda TI; Blanck G
Genes Immun; 2023 Aug; 24(4):194-199. PubMed ID: 37443300
[TBL] [Abstract][Full Text] [Related]
24. Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates.
Hsiang M; Chobrutskiy BI; Diaz M; Huda TI; Creadore S; Zaman S; Cios KJ; Gozlan EC; Blanck G
Transl Oncol; 2021 Jun; 14(6):101069. PubMed ID: 33780706
[TBL] [Abstract][Full Text] [Related]
25. Immunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members.
Diaz MJ; Chobrutskiy BI; Zaman S; Blanck G
Cancer Treat Res Commun; 2020; 24():100196. PubMed ID: 32769037
[TBL] [Abstract][Full Text] [Related]
26. High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer.
Chobrutskiy BI; Chobrutskiy A; Zaman S; Yeagley M; Huda TI; Blanck G
Mol Immunol; 2021 Jul; 135():247-253. PubMed ID: 33933816
[TBL] [Abstract][Full Text] [Related]
27. Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients.
Serana F; Sottini A; Caimi L; Palermo B; Natali PG; Nisticò P; Imberti L
J Transl Med; 2009 Mar; 7():21. PubMed ID: 19317896
[TBL] [Abstract][Full Text] [Related]
28. Poor T-cell receptor β repertoire diversity early posttransplant for severe combined immunodeficiency predicts failure of immune reconstitution.
Delmonte OM; Castagnoli R; Yu J; Dvorak CC; Cowan MJ; Dávila Saldaña BJ; De Ravin SS; Mamcarz E; Chang CK; Daley SR; Griffith LM; Notarangelo LD; Puck JM
J Allergy Clin Immunol; 2022 Mar; 149(3):1113-1119. PubMed ID: 34384841
[TBL] [Abstract][Full Text] [Related]
29. Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma.
Xu Y; Morales AJ; Cargill MJ; Towlerton AMH; Coffey DG; Warren EH; Tykodi SS
Cancer Immunol Immunother; 2019 Dec; 68(12):1979-1993. PubMed ID: 31686124
[TBL] [Abstract][Full Text] [Related]
30. Immune DNA signature of T-cell infiltration in breast tumor exomes.
Levy E; Marty R; Gárate Calderón V; Woo B; Dow M; Armisen R; Carter H; Harismendy O
Sci Rep; 2016 Jul; 6():30064. PubMed ID: 27452728
[TBL] [Abstract][Full Text] [Related]
31. Blood-based T cell receptor anti-viral CDR3s are associated with worse overall survival for neuroblastoma.
Kacsoh DB; Diaz MJ; Gozlan EC; Sahoo A; Song JJ; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12047-12056. PubMed ID: 37421457
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the Heterogeneity of CD4
Zhang T; Duan F; Su D; Ma L; Yang J; Shi B; He X; Ma R; Sun S; Yao X
J Immunol Res; 2020; 2020():3184190. PubMed ID: 33029539
[TBL] [Abstract][Full Text] [Related]
33. TRB sequences targeting ORF1a/b are associated with disease severity in hospitalized COVID-19 patients.
Assmann JLJC; Kolijn PM; Schrijver B; van Gammeren AJ; Loth DW; Ermens TAAM; Dik WA; van der Velden VHJ; Langerak AW
J Leukoc Biol; 2022 Jan; 111(1):283-289. PubMed ID: 33847407
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the Repertoire Features of TCR Beta Chain CDR3 in Human by High-Throughput Sequencing.
Hou X; Wang M; Lu C; Xie Q; Cui G; Chen J; Du Y; Dai Y; Diao H
Cell Physiol Biochem; 2016; 39(2):651-67. PubMed ID: 27442436
[TBL] [Abstract][Full Text] [Related]
35. High throughput sequencing reveals the diversity of TRB-CDR3 repertoire in patients with psoriasis vulgaris.
Cao X; Wa Q; Wang Q; Li L; Liu X; An L; Cai R; Du M; Qiu Y; Han J; Wang C; Wang X; Guo C; Lu Y; Ma X
Int Immunopharmacol; 2016 Nov; 40():487-491. PubMed ID: 27743555
[TBL] [Abstract][Full Text] [Related]
36. T Cell Receptor Beta-Chain Profiling of Tumor Tissue, Peripheral Blood and Regional Lymph Nodes From Patients With Papillary Thyroid Carcinoma.
Wang Y; Liu Y; Chen L; Chen Z; Wang X; Jiang R; Zhao K; He X
Front Immunol; 2021; 12():595355. PubMed ID: 33679738
[No Abstract] [Full Text] [Related]
37. TcR-α recombinations in renal cell carcinoma exome files correlate with an intermediate level of T-cell exhaustion biomarkers.
Mai AT; Tong WL; Tu YN; Blanck G
Int Immunol; 2018 Feb; 30(1):35-40. PubMed ID: 29361059
[TBL] [Abstract][Full Text] [Related]
38. Immune receptor CDR3 chemical features that preserve sequence information are highly efficient in reflecting survival distinctions: A pan-cancer analysis.
Mcbreairty BE; Chobrutskiy BI; Chobrutskiy A; Gozlan EC; Diaz MJ; Blanck G
Biomed Rep; 2022 Aug; 17(2):68. PubMed ID: 35815190
[TBL] [Abstract][Full Text] [Related]
39. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing.
Risitano AM; Maciejewski JP; Green S; Plasilova M; Zeng W; Young NS
Lancet; 2004 Jul 24-30; 364(9431):355-64. PubMed ID: 15276395
[TBL] [Abstract][Full Text] [Related]
40. TRB-J1 usage, in combination with the HLA-A*01:01 allele, represents an apparent survival advantage for uterine corpus endometrial carcinoma: Comparisons with microscopic assessments of lymphocyte infiltrates.
Clark KR; Tong WL; Callahan BM; Yavorski JM; Tu YN; Blanck G
Int J Immunogenet; 2019 Feb; 46(1):31-37. PubMed ID: 30474304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
